EGEsther Gracia-Lavedan

Esther Gracia-Lavedan

*This is an algorithmically generated author record based on publicly available information.

Esther Gracia-Lavedan has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sleep Quality and Sleep Health Before and After Hip or Knee Arthroplasty: A Prospective Cohort Study

    by Jordi Colomina Morales, Adriano D. S. Targa, Mario Henríquez-Beltrán, Esther Gracia-Lavedán, Iván Juez-Garcia, Jordi de Batlle

    Background/Objectives: Sleep quality is a critical determinant of recovery after total joint arthroplasty (TJA), yet multidimensional trajectories of sleep health remain poorly defined. This study aimed to describe the trajectory of sleep health and sleep quality before and after hip or knee arthroplasty, and to examine the influence of sex and surgical site. Methods: A single-centre, prospective cohort study was conducted including 316 patients scheduled for primary hip or knee arthroplasty. Sleep was assessed two months before surgery and at one and six months postoperatively, using the Pittsburgh Sleep Quality Index (PSQI) and the RU-SATED scale. Statistical analyses used linear mixed-effects models with random intercepts for participants. Effect sizes (Cohen’s d) were derived from the residual variance of the mixed models. Results: At baseline, 40% of patients had poor sleep quality. Estimated marginal mean PSQI scores were 5.30 (95% CI: 4.87 to 5.73) preoperatively, 5.71 (5.27 to 6.15) at one month, and 4.19 (3.73 to 4.65) at six months, representing a reduction of 1.11 points (95% CI: 0.69 to 1.54; Cohen’s d = 0.49, 95% CI: 0.30 to 0.68; p < 0.001) from baseline to six months. The proportion of patients with poor sleep quality (PSQI > 5) fell from 40% to 28%, a 12 percentage-point absolute reduction reflecting individual-level transitions across the validated clinical threshold. Exploratory component analyses showed improvements in subjective sleep quality, sleep duration, sleep efficiency, and sleep disturbance. RU-SATED scores increased from 9.72 (95% CI: 9.46 to 9.98) to 10.45 (10.19 to 10.72) at six months, an improvement of 0.73 points (95% CI: 0.47 to 1.00; Cohen’s d = 0.44, 95% CI: 0.27 to 0.60; p < 0.001). Women undergoing knee arthroplasty had significantly worse sleep scores than men at baseline and one month postoperatively, though both sexes followed parallel recovery trajectories (time-by-sex interaction p > 0.30), with the absolute sex difference narrowing by six months. In hip arthroplasty, no significant sex differences or time-by-sex interactions were observed after adjusting for the age imbalance between sexes. Conclusions: Arthroplasty was associated with significant improvements in multidimensional sleep health by six months, though the first postoperative month represents a period of stagnation or slight decline. Women undergoing knee arthroplasty consistently reported worse sleep than men, although the recovery trajectory was parallel between sexes. These findings highlight the potential value of integrating sleep assessment into perioperative care, particularly for women scheduled for knee arthroplasty, though whether targeted sleep interventions improve clinical outcomes remains to be established through prospective intervention studies.

  • Heterogeneous Effects of Continuous Positive Airway Pressure in Non-Sleepy Obstructive Sleep Apnea on Cardiovascular Disease Outcomes: Post Hoc Machine Learning Analysis of the ISAACC Trial (ECSACT Study)

    by Oren Cohen, Manuel Sánchez-De-La-Torre, Zainab Al-Taie, Samira Khan, Vaishnavi Kundel, Jason C. Kovacic, Esther Gracia-Lavedan, Jordi De Batlle, Girish Nadkarni, Ferran Barbé, et al.

    Rationale: Randomized controlled trials of continuous positive airway pressure (CPAP) therapy for cardiovascular disease (CVD) prevention among patients with obstructive sleep apnea (OSA) have been largely neutral. However, given that OSA is a heterogeneous disease, there may be unidentified subgroups demonstrating differential treatment effects. Objectives: We sought to apply a novel data-drive approach to identify nonsleepy OSA subgroups with heterogeneous effects of CPAP on CVD outcomes within the Impact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome (ISAACC) study. Methods: Participants were randomly partitioned into two datasets. One for training (70%) our machine-learning model and a second (30%) for validation of significant findings. Model-based recursive partitioning was applied to identify subgroups with heterogeneous treatment effects. Survival analysis was conducted to compare treatment (CPAP vs. usual care [UC]) outcomes within subgroups. Results: A total of 1,224 nonsleepy OSA participants were included. Of 55 features entered into our model, only two appeared in the final model (i.e., average OSA event duration and hypercholesterolemia). Among participants at or below the model-derived average event duration threshold (19.5 s), CPAP was protective for a composite of CVD events (training hazard ratio [HR], 0.46; P = 0.002). For those with longer event duration (>19.5 s), an additional split occurred by hypercholesterolemia status. Among participants with longer event duration and hypercholesterolemia, CPAP resulted in more CVD events compared with UC (training HR, 2.24; P = 0.011). The point estimate for this harmful signal was also replicated in the testing dataset (HR, 1.83; P = 0.118). Conclusions: We discovered subgroups of nonsleepy OSA participants within the ISAACC study with heterogeneous effects of CPAP. Among the training dataset, those with longer OSA event duration and hypercholesterolemia had nearly 2.5 times more CVD events with CPAP compared with UC, whereas those with shorter OSA event duration had roughly half the rate of CVD events if randomized to CPAP.


  • Open Access

    Multidisciplinary virtual management of pulmonary nodules

    by D. Polanco, J. González, E. Gracia-Lavedan, L. Pinilla, R. Plana, M. Molina, M. Pardina, F. Barbé

    Multidisciplinary nodule clinics provide high-quality care and favor adherence to guidelines. Virtual care has shown savings benefits along with patient satisfaction. Our aim is to describe the first year of operation of a multidisciplinary virtual lung nodule clinic, the population evaluated and issued decisions. Secondarily, among discharged patients, we aimed to analyze their follow-up prior to the existence of our consultation, evaluating its adherence to guidelines. Observational study including all patients evaluated at the Virtual Lung Nodule Clinic (VLNC) (March 2018- March 2019). Clinical and radiological data were recorded. Recommendations, based on 2017 Fleischner Society guidelines, were categorized into follow-up, discharge or referral to lung cancer consultation. Discharged patients were classified according to adherence to guidelines of their previous management, into adequate, prolonged and non-indicated follow-up. A total of 365 patients (58.9% men; median age 64.0 years) were included. Sixty-four percent had smoking history and 23% had chronic obstructive pulmonary disease (COPD). Most nodules were solid (87.4%) and multiple (57.5%). The median diameter was 6.00 mm. 43.8% of patients were discharged following first VLNC evaluation. Among them, 27.5% had received appropriate follow-up, but 66.9% had received poor management. Patients with prolonged follow-up (33.1%) were older (67.0 vs 60.5 years) and had larger nodules (6.00 mm vs 5.00). Non-indicated follow-up patients (33.8%) were more non-smokers (77.8% vs 31.8%) and presented smaller nodules (4.00 vs 5.00 mm). During its first year of operation, the VLNC has evaluated a population with a relevant risk profile for lung cancer development, management of which should be cautious and adhere to guidelines. After the first VLNC assessment, approximately one-half of this population was discharged. It was noticeable that previous follow-up of discharged patients was found poorly adherent to guidelines, with a marked tendency to overmanagement.


  • Open Access

    Metabolipidomic Analysis in Patients with Obstructive Sleep Apnea Discloses a Circulating Metabotype of Non-Dipping Blood Pressure

    by Lucía Pinilla, Iván D. Benítez, Esther Gracia-Lavedan, Gerard Torres, Olga Mínguez, Rafaela Vaca, Mariona Jové, Joaquim Sol, Reinald Pamplona, Ferran Barbé, et al.

    A non-dipping blood pressure (BP) pattern, which is frequently present in patients with obstructive sleep apnea (OSA), confers high cardiovascular risk. The mechanisms connecting these two conditions remain unclear. In the present study we performed a comprehensive analysis of the blood metabolipidome that aims to provide new insights into the molecular link between OSA and the dysregulation of circadian BP rhythmicity. This was an observational prospective longitudinal study involving adults with suspected OSA who were subjected to full polysomnography (PSG). Patients with an apnea–hypopnea index ≥ 5 events/h were included. Fasting plasma samples were obtained the morning after PSG. Based on the dipping ratio (DR; ratio of night/day BP values) measured via 24 h ambulatory BP monitoring, two groups were established: dippers (DR ≤ 0.9) and non-dippers (DR > 0.9). Treatment recommendations for OSA followed the clinical guidelines. Untargeted metabolomic and lipidomic analyses were performed in plasma samples via liquid chromatography–tandem mass spectrometry. Non-dipper patients represented 53.7% of the cohort (88/164 patients). A set of 31 metabolic species and 13 lipidic species were differentially detected between OSA patients who present a physiologic nocturnal BP decrease and those with abnormal BP dipping. Among the 44 differentially abundant plasma compounds, 25 were putatively identified, notably glycerophospholipids, glycolipids, sterols, and fatty acid derivates. Multivariate analysis defined a specific metabotype of non-dipping BP, which showed a significant dose-response relationship with PSG parameters of OSA severity, and with BP dipping changes after 6 months of OSA treatment with continuous positive airway pressure (CPAP). Bioinformatic analyses revealed that the identified metabolipidomic profile was found to be implicated in multiple systemic biological pathways, with potential physiopathologic implications for the circadian control of BP among individuals with OSA.


  • Open Access

    Sleep and breast and prostate cancer risk in the MCC-Spain study

    by Michelle C. Turner, Esther Gracia-Lavedan, Kyriaki Papantoniou, Nuria Aragonés, Gemma Castaño-Vinyals, Trinidad Dierssen-Sotos, Pilar Amiano, Eva Ardanaz, Alba Marcos-Delgado, Ana Molina-Barceló, et al.

    Breast and prostate cancers have been associated with circadian disruption. Some previous studies examined associations of sleep duration and breast or prostate cancer risk though findings remain inconsistent. This study examines associations of a range of detailed sleep characteristics and breast and prostate cancer risk in a large-scale population-based case–control study, MCC-Spain. A total of 1738 incident breast cancer cases, 1112 prostate cancer cases and frequency matched controls (n = 1910, and 1493 respectively) were recruited. Detailed data on habitual sleep duration, quality, timing, and daytime napping (“siesta”) were collected at recruitment. Additional data on sleep habits during both the previous year and at age 40 years were also subsequently captured. Adjusted odds ratios (ORs) and 95% confidence intervals (CI) were estimated. There were no associations of habitual sleep duration (h), timing of sleep, or any or specific sleep problems, and either breast and prostate cancer risk. There was a significant positive association of ever taking habitual siestas at recruitment and breast cancer risk (OR = 1.22, 95% CI 1.06–1.42), which strengthened with increased frequency or duration. There were also significant positive associations observed for both breast and prostate cancer, among those reporting recent sleep problems, but not sleep problems at age 40 years, in a subsequent circadian questionnaire. Adverse associations with siesta and disturbed sleep during the previous year likely reflect symptoms of developing/diagnosed cancer and comorbidities. Overall, there was no clear association between various sleep characteristics and breast or prostate cancer risk observed.


  • Open Access

    Lung Function Impairment Is Related to Subclinical Atherosclerosis Only in Active Smokers

    by Jessica González, Esther Gracia-Lavedan, Silvia Gómez, Silvia Barril, Pere Godoy, Marcelino Bermúdez-López, Angels Betriu, Elvira Fernández, Albert Lecube, Reinald Pamplona, et al.

    Background: Although an association between lung function and subclinical atherosclerosis has been reported, it remains unclear whether this association is only driven by tobacco smoking. We aimed to assess this in a population with at least one cardiovascular risk factor. Methods: We recruited 6209 subjects aged between 45 and 70 years with at least one cardiovascular risk factor (excluding diabetes mellitus) participating in the ILERVAS project 2015–2018. Lung function was determined by spirometry. Subclinical atherosclerosis was assessed with the ankle–brachial index (ABI) and the presence of carotid and femoral plaques measured by ultrasound. Results: A total of 5927 subjects were included: 49% male, median (p25–p75) age 57 years (52–62). Plaques were found in 4337 (73.2%) of the subjects. The patients with atherosclerosis showed worse lung function: median forced expiratory volume in one second (FEV1) 95% and forced vital capacity (FVC) 94% in the patients with plaques vs. 99% and 98% in the other patients (p < 0.001). Adjusted models stratified by smoking status showed that being in the lower quartiles of FEV1 % was associated with carotid and femoral plaques (OR 1.599, p = 0.005; and OR 1.654, p = 0.006), whereas FVC % was inversely associated with carotid plaques (OR 0.967, p = 0.041). A pathological ABI was associated with worse FEV1 (OR 1.971, p = 0.038) and the presence of airway obstruction (OR 1.658, p = 0.015). However, these differences were restricted to current smokers. Conclusions: Lung function impairment was correlated with subclinical atherosclerosis only in current smokers. This highlights the unique role of smoking-related vascular and pulmonary dysfunction in early stages of pulmonary and cardiovascular afflictions.


  • Open Access

    Exposure to drinking water trihalomethanes and nitrate and the risk of brain tumours in young people

    by Angela Zumel-Marne, Gemma Castaño-Vinyals, Juan Alguacil, Cristina M. Villanueva, Milena Maule, Esther Gracia-Lavedan, Franco Momoli, Daniel Krewski, Charmaine Mohipp, Eleni Petridou, et al.


  • Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer

    by Dora Romaguera, Sílvia Fernández-Barrés, Esther Gracia-Lavedán, Eva Vendrell, Mikel Azpiri, Emma Ruiz-Moreno, Vicente Martín, Inés Gómez-Acebo, Mireia Obón, Amaia Molinuevo, et al.


  • Open Access

    The Dietary Inflammatory Index and Chronic Lymphocytic Leukaemia in the MCC Spain Study

    by José Carlos Flores, Esther Gracia-Lavedan, Yolanda Benavente, Pilar Amiano, Dora Romaguera, Laura Costas, Claudia Robles, Eva Gonzalez-Barca, Esmeralda de la Banda, Esther Alonso, et al.

    Chronic inflammation plays a role in the development of chronic lymphocytic leukaemia (CLL), and diet might modulate chronic inflammation. This study aims to evaluate the association between the dietary inflammatory index (DII®) and CLL. A total of 366 CLL cases and 1643 controls of the Spanish multicase-control (MCC) Spain study were included. The inflammatory potential of the diet was assessed using the energy-adjusted dietary inflammatory index (E-DII) based on 30 items from a validated semi-quantitative food frequency questionnaire. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression models controlling for potential confounders. Overall, a modest, non-statistically significant, positive association was observed between CLL and E-DII scores (OR for a one-unit increase in E-DII: 1.05 (CI 95%: 0.99, 1.12), p-value = 0.09 and by tertiles: ORT2vsT1: 1.20 (CI 95%: 0.90, 1.59); OR T3vsT1: 1.21 (CI 95%: 0.90, 1.62), p trend = 0.21). These results were independent from disease severity (p-het: 0.70), time from diagnosis (p-het: 0.67) and CLL treatment received (p-het: 0.56). No interactions were detected. In conclusion, the consumption of a diet with high pro-inflammatory components was not significantly associated with CLL. Changes towards a more pro-inflammatory dietary pattern in younger generations not included here warrant future research.


  • Open Access

    Dietary Inflammatory Index, Dietary Non-Enzymatic Antioxidant Capacity, and Colorectal and Breast Cancer Risk (MCC-Spain Study)

    by Mireia Obón-Santacana, Dora Romaguera, Esther Gracia-Lavedan, Amaia Molinuevo, Esther Molina-Montes, Nitin Shivappa, James R. Hebert, Adonina Tardón, Gemma Castaño-Vinyals, Ferran Moratalla, et al.

    Inflammation and antioxidant capacity have been associated with colorectal and breast cancer. We computed the dietary inflammatory index (DII®), and the total dietary non-enzymatic antioxidant capacity (NEAC) and associated them with colorectal and breast cancer risk in the population-based multi case-control study in Spain (MCC-Spain). We included 1852 colorectal cancer and 1567 breast cancer cases, and 3447 and 1486 population controls, respectively. DII score and NEAC were derived using data from a semi-quantitative validated food frequency questionnaire. Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (95%CI) for energy-adjusted DII (E-DII), and a score combining E-DII and NEAC. E-DII was associated with colorectal cancer risk (OR = 1.93, highest quartile versus lowest, 95%CI:1.60–2.32; p-trend: 0.10). The combined score of high E-DII scores and low antioxidant values were associated with colorectal cancer risk (OR = 1.48, highest quartile versus lowest, 95%CI: 1.26–1.74; p-trend: <0.001), but not breast cancer. This study provides evidence that a pro-inflammatory diet is associated with increased colorectal cancer risk while findings for breast cancer were less consistent.